Anocca AB, a Sodertalje, Sweden-based developer of therapeutics for cancer leveraging the potential of T-cell immunotherapy, closed a USD 47m (SEK 400m) Series B financing.
Backers included Swedbank Robur Ny Teknik, Ramsbury Invest and family offices including those of Harald Mix and Robert Andreen and existing investors including Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano.
The company intends to use the funds to further advance its industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials.
Led by CEO and co-founder Reagan Jarvis, Anocca leverages a cellular biology platform that replicates human T-cell biology in the laboratory, to generate targeted T-cell therapies with broad applicability in oncology, infectious diseases and autoimmune disorders. The platform is comprised of a number of proprietary cell biology and molecular genetics technologies and enables the high-precision analysis needed to develop highly targeted therapeutics that leverage T-cell immunity. The platform is underpinned by proprietary, fully integrated, information management and bioinformatic software tools developed in-house.
Anocca has delivered a broad pipeline of T-cell receptor (TCR) assets to generate novel TCR-modified T-cell therapies (TCR-T) against multiple antigen classes, including targets that are shared amongst tumours, against specific genetic mutations that drive cancer, and against viruses that cause cancer. TCR-T cellular therapies can unlock an immense target space inaccessible to biologics and CAR-T therapies and is emerging as an important treatment modality for many forms of cancer.
The company has a team of over 65 employees.